Search

everythinglearnresearchcommunity

for

Search:↓

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

Neuropathic pain is common in long COVID patients, especially those with depression or severe COVID-19.

18% of COVID-19 survivors experience PTSD, with risk factors including age, gender, smoking, and lung damage.

Hair shedding after COVID-19 is more linked to the disease's severity and inflammation rather than hormones, with women at higher risk.

Some COVID-19 patients have skin issues, with men, ICU patients, and those on multiple antibiotics at higher death risk; in-person skin checks by dermatologists are more effective.

Certain skin symptoms in COVID-19 patients may indicate a more severe illness.

COVID-19 patients in Thailand typically started losing hair about 30 days after infection, with women experiencing more severe hair loss.

COVID-19 can cause temporary hair loss in some patients, affecting their quality of life.

Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.

Hair loss is not clearly linked to COVID-19 vaccination in Egyptians.

Post-COVID-19 patients often experience musculoskeletal issues, fitness decline, behavioral changes, chest pain, cough, hair loss, and nervous system problems.

Older men with diabetes were more likely to get severe COVID-19 and needed treatments like antivirals for about 2-3 weeks.

Older men with diabetes were more likely to get severe COVID-19 and needed treatments like antivirals for about 2-3 weeks.

COVID-19 can cause skin problems.

Certain plant compounds can help prevent and treat a virus in pigs.

COVID-19 severely affects older adults with chronic heart, lung, or metabolic diseases.

COVID-19 can cause over 50 long-term symptoms, with fatigue and headache being the most common.

COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.

Old age, male sex, smoking, and obesity may affect COVID-19 severity, but more research is needed.

Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.

COVID-19 may cause hair loss, often after recovery, with androgenetic alopecia being the most common type.

COVID-19 may worsen hair loss, and Nourkrin® could be a safe treatment option, but more research is needed.

Low testosterone and SHBG levels are linked to higher COVID-19 death rates.

COVID-19 infection can significantly cause temporary hair loss.

Canakinumab's effect on COVID-19 outcomes is unclear.

COVID-19 vaccines are safe and highly effective for children, with inactivated vaccines being slightly better.

Long COVID affects about 27% of patients, with higher risk for women, lower education, and certain income levels.

Some people still have COVID-19 symptoms after 90 days, especially older patients and those with severe initial symptoms, but most return to normal.

Certain immune responses may cause ongoing COVID-19 symptoms like fatigue and brain fog.

COVID-19 can cause hair loss, and managing it involves counseling, diet changes, and treatments.